

Risperdal Consta[®] (risperidone) – First-time generic

- On December 12, 2023, [Teva launched](#) an [AB-rated](#) generic version of Janssen's [Risperdal Consta \(risperidone\)](#) long-acting intramuscular injection.
- Risperdal Consta is approved for the treatment of schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder.
- Risperidone is also available generically as a [tablet](#), [oral solution](#), and [orally disintegrating tablet](#), and brand extended-release injectable suspension ([Perseris[®]](#), [Rykindo[®]](#), [Uzedy[®]](#)).
 - The tablet, oral solution, and orally disintegrating tablet carry the same indications as Risperdal Consta and are also approved for treatment of irritability associated with autistic disorder.
 - Perseris and Uzedy are approved for the treatment of schizophrenia in adults.
 - Rykindo carries the same indications as Risperdal Consta.
- Risperdal Consta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.